Shield Therapeutics (LON:STX) Earns “Buy” Rating from Peel Hunt

Peel Hunt restated their buy rating on shares of Shield Therapeutics (LON:STX) in a research report sent to investors on Wednesday, MarketBeat reports. They currently have a GBX 15 price objective on the stock.

Shield Therapeutics Stock Performance

Shares of STX stock opened at GBX 7.80 on Wednesday. The company has a market capitalization of £81.25 million, a price-to-earnings ratio of -390.00 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The company has a 50-day simple moving average of GBX 6.73 and a 200 day simple moving average of GBX 4.12. Shield Therapeutics has a 52 week low of GBX 2.10 and a 52 week high of GBX 9.10.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.